Skip to main content
TSHA logo

TSHA · Taysha Gene Therapies, Inc. · Debt

Track TSHA — free
$4.25 +0.24 (+5.99%) At close · Oct 27 Q2 2026 earnings call transcript
Market Cap
$1.36B
Shares
325.83M
Volume · Oct 27 2.82M Avg daily vol (3M) 3.55M

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Finance lease liabilities 2026-06-30 USD 167,000 10-Q filed 2026-08-11
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current finance lease liabilities
USD 167,000
Noncurrent debt carrying amount 2026-06-30 USD 49,260,000 10-Q filed 2026-08-11
Operating lease liabilities 2026-06-30 USD 7,287,000 10-Q filed 2026-08-11
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 996,000
Noncurrent operating lease liabilities
USD 6,291,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Key facts CIK 1806310 CUSIP 877619106 13F (30d) 19 filings 19 filers Visit website Investor relations